GOLDMAN SACHS GROUP INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$37,581,390
+113.1%
1,425,157
+39.0%
0.01%
+100.0%
Q2 2023$17,638,049
+9.1%
1,025,468
+5.2%
0.00%
+33.3%
Q1 2023$16,169,330
+56.6%
975,231
-28.0%
0.00%
+50.0%
Q4 2022$10,327,356
-14.1%
1,355,296
+12.0%
0.00%
-33.3%
Q3 2022$12,029,000
+38.6%
1,210,210
+26.7%
0.00%
+50.0%
Q2 2022$8,676,000
+18.3%
955,512
+32.2%
0.00%0.0%
Q1 2022$7,336,000
-38.3%
722,747
+1.4%
0.00%0.0%
Q4 2021$11,892,000
-59.0%
712,908
+15.3%
0.00%
-66.7%
Q3 2021$28,991,000
+10.2%
618,539
+43.3%
0.01%0.0%
Q2 2021$26,313,000
-29.6%
431,633
-28.8%
0.01%
-33.3%
Q1 2021$37,364,000
-16.1%
606,568
-3.2%
0.01%
-18.2%
Q4 2020$44,549,000
+108.6%
626,485
+10.0%
0.01%
+83.3%
Q3 2020$21,361,000
+75.4%
569,327
+52.4%
0.01%
+50.0%
Q2 2020$12,179,000
-1.8%
373,469
-12.7%
0.00%0.0%
Q1 2020$12,399,000
+56.5%
427,559
+89.1%
0.00%
+100.0%
Q4 2019$7,924,000
+116.0%
226,059
+32.3%
0.00%
+100.0%
Q3 2019$3,669,000
-1.7%
170,882
+23.5%
0.00%0.0%
Q2 2019$3,731,000138,3380.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders